Nasal Spray Therapy Shows Promise in Reducing Brain Inflammation and Restoring Memory
Similar Articles
Engineered Nanoparticles Show Promise in Restoring Brain Waste Removal in Alzheimer's Mouse Model
Experimental Compounds Show Promise in Reducing Brain Inflammation Linked to Alzheimer's
Arginine Shows Promise in Reducing Alzheimer's Plaques in Animal Studies
Researchers Identify Brain Cell Process That Removes Alzheimer's Plaques in Mice
Researchers Restore Memory in Dementia Models by Fixing Mitochondrial Activity
A new nasal spray therapy, developed by researchers at Texas A&M University, has shown potential to reduce chronic brain inflammation and restore memory function. The treatment uses extracellular vesicles (EVs) to deliver therapeutic agents directly to brain tissue, bypassing protective barriers. Positive effects from a two-dose regimen lasted for months, offering a potential new approach for conditions like dementia.
Facts First
- A nasal spray therapy restored memory and reduced chronic inflammation in a study led by Texas A&M University researchers.
- The treatment uses extracellular vesicles (EVs) loaded with microRNAs to target and suppress inflammatory pathways in the brain.
- Behavioral testing showed improved performance in memory tasks in treated models compared to untreated controls.
- The effects of a two-dose treatment lasted for months, suggesting durable therapeutic potential.
- The research team has filed a U.S. patent for the therapy, supported by the National Institute on Aging (NIA).
What Happened
Researchers at Texas A&M University conducted a study on a nasal spray designed to reduce brain inflammation. The study, led by Dr. Ashok Shetty and senior research scientists Dr. Madhu Leelavathi Narayana and Dr. Maheedhar Kodali, reported that the treatment restored memory, reduced chronic inflammation, and improved brain cell function after two doses. The findings were published in the Journal of Extracellular Vesicles.
Why this Matters to You
The therapy targets immune cells to suppress inflammatory systems, specifically the NLRP3 inflammasome and the cGAS-STING signaling pathways. This could be relevant for conditions like dementia, where annual cases in the United States are projected to increase from approximately 514,000 in 2020 to around 1 million by 2060. If this therapy progresses, it may offer a new, non-invasive treatment option for neurodegenerative diseases that affect memory and cognitive function.
What's Next
The research team has filed a U.S. patent related to the therapy. Further development and clinical trials may be needed to determine its efficacy and safety for human use. The therapy's ability to restore mitochondrial activity and its durable effects, lasting for months after two doses, suggest it could become a significant advancement in treating brain inflammation.